{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:39:50Z","timestamp":1770914390749,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Renal cell carcinoma (RCC) is a heterogenous disease composed of several different cancer types characterized by distinct histologies and genetic alterations, including mutation of the Krebs cycle enzyme genes for fumarate hydratase and succinate dehydrogenase (SDH). This report describes a patient with multifocal renal tumors that presented with a novel, biphasic histologic morphology with one component consisting of small cells growing in a diffuse pattern occasionally forming glandular and cystic structures, reminiscent of type 1 papillary RCC, and the other component having larger cells with abundant eosinophilic and clear cytoplasm and appearing in a solid pattern of growth. Genetic analysis of multiple tumors showed that all had a somatic mutation of the <jats:italic toggle=\"yes\">IDH2<\/jats:italic> gene that created the known pathogenic, gain-of-function p.R172M alteration that results in abnormal accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). Analysis of multiple tumors demonstrated highly elevated levels of 2-HG and a CpG island methylator phenotype that is characteristic of 2-HG-related inhibition of the Ten-eleven translocation (TET) family of DNA demethylases. In combination with fumarate hydratase\u2013deficient and succinate dehydrogenase\u2013deficient RCCs that have increased levels of the fumarate and succinate oncometabolites, respectively, the mutation of isocitrate dehydrogenase 2 represents the third Krebs cycle enzyme alteration to be associated with oncometabolite-induced RCC tumorigenesis. This study associates the discovery of a new histologic presentation of RCC with the first report of an <jats:italic toggle=\"yes\">IDH2<\/jats:italic> gain-of-function mutation in RCC.<\/jats:p>","DOI":"10.1097\/pas.0000000000001611","type":"journal-article","created":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T21:01:29Z","timestamp":1604869289000},"page":"137-142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm"],"prefix":"10.1097","volume":"45","author":[{"given":"Maria J.","family":"Merino","sequence":"first","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Ricketts","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Moreno","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa W.M.","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Cancer Biology and Markey Cancer Center, Center for Environmental and Systems Biochemistry, University of Kentucky, Lexington, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew N.","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Cancer Biology and Markey Cancer Center, Center for Environmental and Systems Biochemistry, University of Kentucky, Lexington, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Meltzer","sequence":"additional","affiliation":[{"name":"Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy D.","family":"Vocke","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Crooks","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Linehan","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"610.e1","DOI":"10.1016\/j.ccell.2016.03.021","article-title":"SnapShot: renal cell carcinoma","volume":"29","author":"Ricketts","year":"2016","journal-title":"Cancer Cell"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.seminoncol.2016.09.001","article-title":"Genetic predisposition to kidney cancer","volume":"43","author":"Schmidt","year":"2016","journal-title":"Semin Oncol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrneph.2017.59","article-title":"Metabolic reprogramming in clear cell renal cell carcinoma","volume":"13","author":"Wettersten","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/PAS.0000000000000292","article-title":"Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients","volume":"38","author":"Gill","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0065-230X(08)60316-4","article-title":"Molecular cytogenetics of renal cell tumors","volume":"62","author":"Kovacs","year":"1993","journal-title":"Adv Cancer Res"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/djn254","article-title":"Germline SDHB mutations and familial renal cell carcinoma","volume":"100","author":"Ricketts","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"268ra177","DOI":"10.1126\/scitranslmed.3009961","article-title":"Recurrent epimutation of SDHC in gastrointestinal stromal tumors","volume":"6","author":"Killian","year":"2014","journal-title":"Sci Transl Med"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"e0149833","DOI":"10.1371\/journal.pone.0149833","article-title":"Whole genome sequencing of newly established pancreatic cancer lines identifies novel somatic mutation (c.2587G>A) in axon guidance receptor plexin A1 as enhancer of proliferation and invasion","volume":"11","author":"Sorber","year":"2016","journal-title":"PLoS ONE"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-4939-1258-2_11","article-title":"Stable isotope-labeled tracers for metabolic pathway elucidation by GC-MS and FT-MS","volume":"1198","author":"Higashi","year":"2014","journal-title":"Methods Mol Biol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10858-011-9484-6","article-title":"NMR-based stable isotope resolved metabolomics in systems biochemistry","volume":"49","author":"Fan","year":"2011","journal-title":"J Biomol NMR"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41467-017-01518-z","article-title":"Noninvasive liquid diet delivery of stable isotopes into mouse models for deep metabolic network tracing","volume":"8","author":"Sun","year":"2017","journal-title":"Nat Commun"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/epi.09.14","article-title":"Genome-wide DNA methylation profiling using Infinium (R) assay","volume":"1","author":"Bibikova","year":"2009","journal-title":"Epigenomics"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng.3146","article-title":"Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes","volume":"47","author":"Durinck","year":"2015","journal-title":"Nat Genet"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S70716","article-title":"IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives","volume":"7","author":"Mondesir","year":"2016","journal-title":"J Blood Med"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:05:14Z","timestamp":1749420314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001611","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}